Navigation Links
While focusing on heart disease, researchers discover new tactic against fatal muscular dystrophy
Date:2/8/2009

NEW YORK (Feb. 8, 2009) Based on a striking similarity between heart disease and Duchenne muscular dystrophy, researchers at Columbia University Medical Center have discovered that a new class of experimental drugs for heart failure may also help treat the fatal muscular disorder.

At first glance, heart failure and the muscle-wasting Duchenne disease couldn't appear more dissimilar. Duchenne affects boys usually before the age of 6, destroying their muscle cells. The boys become progressively weaker through their teens and usually die in their twenties. In people without Duchenne, heart failure typically starts much later in life, robbing the heart's pumping ability in the 7th, 8th or 9th decade of life.

But the new study found that the muscle cells affected in both diseases have sprung the same microscopic leak that ultimately weakens skeletal muscle in Duchenne and cardiac muscle in heart failure. The leak lets calcium slowly seep into the skeletal muscle cells, which are damaged from the excess calcium in Duchenne. In people with chronic heart failure, a similar calcium leak continuously weakens the force produced by the heart and also turns on a protein-digesting enzyme that damages its muscle fibers.

Andrew Marks, M.D., the study's leader, hypothesized that a new class of experimental drugs developed at CUMC which he had designed to plug the leak in the heart could also work for Duchenne.

The drugs, when given to mice with Duchenne, dramatically improved muscle strength and reduced the number of damaged muscle cells.

"This was extremely exciting to us," says Dr. Marks, chair of the Department of Physiology & Cellular Biophysics and Clyde and Helen Wu Professor of Molecular Cardiology. "If it works in people, our drug won't be a cure, but it could slow the pace of muscle degeneration and extend the lives of people with Duchenne."

The study was published online Feb. 8 in Nature Medicine. Though
'/>"/>

Contact: Alex Lyda
mal2133@columbia.edu
212-305-0820
Columbia University Medical Center
Source:Eurekalert

Page: 1 2

Related biology news :

1. U-M ballast-free ship could cut costs while blocking aquatic invaders
2. Fueling ethanol production while protecting water quality
3. Johns Hopkins researchers detect sweet cacophony while listening to cellular cross-talk
4. ESA satellites focusing on the Arctic
5. Abnormal fat metabolism underlies heart problems in diabetic patients
6. High blood pressure, low energy -- a recipe for heart failure
7. Human derived stem cells can repair rat hearts damaged by heart attack
8. Geron Demonstrates hESC-derived cardiomyocytes improve heart function after myocardial infarction
9. Heart of Herschel to be presented to media
10. Minimally invasive heart surgery research wins NIH award
11. A step toward tissue-engineered heart structures for children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... PAUL (August 28, 2014) Researchers at the University ... facioscapulohumeral muscular dystrophy (FSHD) to be used for muscle ... of potential therapies for FSHD. , The research is ... Cell Reports . , There is no treatment for ... most common type of muscular dystrophy. FSHD is an ...
(Date:8/28/2014)... 2014  Privacy Advocate and Senior Staff Attorney at ... joins the lineup of biometric and mobile commerce experts ... Executive Summit in Tampa, Florida ... speakers include Steven Rahman, Director, Technology and Strategy at Samsung, ... The theme of this year,s event is Mobility at ...
(Date:8/28/2014)... WASHINGTON, Aug. 28, 2014A new method for measuring and ... help doctors and researchers better understand how drug abuse ... surgery and tissue engineering, and lead to better treatment ... by a team of researchers from Stony Brook University ... of Health, was published today in The Optical Society,s ...
Breaking Biology News(10 mins):UMN researchers find animal model for understudied type of muscular dystrophy 2Biometrics UnPlugged Welcomes the Electronic Frontier Foundation's Jennifer Lynch to the Mobility at the Crossroads of Commerce and Privacy Summit 2This is your brain's blood vessels on drugs 2This is your brain's blood vessels on drugs 3
... flowers and their pollinators have resulted in a ... pollinators such as bees, flies or butterflies to ... evolved intriguing mechanisms and attractants, of which nectar ... discovered that nectars of flowers pollinated by butterflies ...
... in the human gut adaptively shifts more than a ... host's diet changes from sugar to complex carbohydrates. , ... to survive rapidly changing nutrient conditions but also helps ... complex microbial society, according to researchers at Washington University ...
... novel,vaccine that uses immune cells as factories to produce ... breast cancers, say researchers at,The University of Texas M. ... is a protein often present / surexpressed in ... Breast Cancer Research,on Nov. 29, 2004, showed that the ...
Cached Biology News:Highly adaptable genome in gut bacterium key to intestinal health 2Highly adaptable genome in gut bacterium key to intestinal health 3Gene Vaccine Protects Mice Against Development Of Her2/neu Breast Cancer 2Gene Vaccine Protects Mice Against Development Of Her2/neu Breast Cancer 3
(Date:8/28/2014)... 28, 2014 Earlier this month, ... in partnership with the U.S. Air Force on the ... results indicated that this type of fuel made from ... will be important to America’s Eco friendly future. In ... a mandate to become independent of foreign oil over ...
(Date:8/28/2014)... 28, 2014 Whitehouse Laboratories is excited ... partnership with PTI Inspection Systems that will ... of the art leak testing method development and validation ... currently available. As part of this agreement, Whitehouse Labs ... Leak Detection Instrument developed and manufactured by PTI. ...
(Date:8/27/2014)... Rhythm, a biopharmaceutical company developing peptide therapeutics ... in metabolic disorders, announced today that it has filed ... Securities and Exchange Commission (SEC) relating to the proposed ... The number of shares to be offered and the ... determined. Citigroup and Cowen and Company will ...
(Date:8/27/2014)... 27, 2014   MSC , a healthcare performance ... announced the appointment of Mary Beth Loesch ... years of experience preparing companies for rapid growth and ... Vice President of Corporate Development and Healthcare. In that ... , as well as corporate strategy and marketing. Previously, ...
Breaking Biology Technology:Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 2Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 4Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 5Whitehouse Labs Renews Partnership with PTI Inspection Systems 2Whitehouse Labs Renews Partnership with PTI Inspection Systems 3Rhythm Files Registration Statement for Proposed Initial Public Offering 2MSC names Mary Beth Loesch President and CEO 2
... and Two Clinical Candidates Featured -, SOUTH ... a privately held company focused on the discovery,and ... four abstracts have been selected for presentation at ... held in San Diego on,April 12-16, 2008., ...
... Mass., Feb. 12 Mersana, a cancer,therapeutics company, announced ... as Chief Scientific Officer., "We are thrilled that ... said,Julie A. Olson, President and CEO at Mersana. "His ... drug systems are an,ideal match for Mersana. In addition ...
... BOSTON, Feb. 11 PAREXEL International,Corporation (Nasdaq: PRXL ... a 2-for-1 split of its Common Stock, which will ... Holders of PAREXEL,s Common Stock will receive one additional ... held on the record date of,February 22, 2008. The ...
Cached Biology Technology:Raven biotechnologies to Provide Updates on Oncology Pipeline With Four AACR Presentations 2Raven biotechnologies to Provide Updates on Oncology Pipeline With Four AACR Presentations 3Mersana Therapeutics, Inc. Appoints Chief Scientific Officer, Timothy B. Lowinger, Ph.D. 2PAREXEL International Announces 2-For-1 Stock Split 2PAREXEL International Announces 2-For-1 Stock Split 3
... different human fetal normal tissues are ... upon request. Customers can choose ... set, and pay 70% of the ... P Set products are for research ...
... delivery of buffer and fixative results ... version. In Vivo Manual Perfusion Fixation ... of buffer and fixative results in ... use and clean--Complete system with everything ...
Mouse IL-31 RA Biotinylated Affinity Purified PAb...
... plus assay system offers the ... Designed for batch-processing systems, Long ... density microplates such as 384-well ... Convenient storage conditions ( 2 ...
Biology Products: